| Ytd | -69.37% | |
| 1y | -76.96% |
| Open | 9.50 | Prev Close | 9.52 | Low | 9.16 | High | 9.50 | Mkt Cap | 417.84M |
| Vol | 24.51K | Avg Vol | 36.41K | EPS | 0.07 | P/E | 137.57 | Forward P/E | N/A |
| Beta | 5.15 | Short Ratio | 1.79 | Inst. Own | 4.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-28 | 50-d Avg | 19.70 | 200-d Avg | 25.07 | 1yr Est | 0.00 |
Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock stre
Oversold health care stocks: EVMN, NNNN, NAUT. RSI <30 shows they may be undervalued. EVMN drop
Health care sector's oversold stocks present buying opportunity; RSI below 30 signals oversold,
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a
Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) and Oncocyte (NASDAQ: IMDX - Get Free Report) a
Oncocyte (NASDAQ: IMDX - Get Free Report) and Anbio Biotechnology (NASDAQ: NNNN - Get Free Report) a